- The FDA has recommended Pharnext SA (OTCPK:PNEXF) to conduct an additional Phase 3 study to evaluate PXT3003 in Charcot-Marie-Tooth Disease Type 1A ("CMT1A").
- More news on: Pharnext SA, Healthcare stocks news, Read more ...
home / stock / pnexf / pnexf news
Market Wire News is a media platform, the information on this page was provided by SeekingAlpha via Quote Media. Read our full disclaimer.
When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
News, Short Squeeze, Breakout and More Instantly...
Pharnext SA Company Name:
PNEXF Stock Symbol:
Market:
PARIS, FRANCE / ACCESSWIRE / January 4, 2023 / Pharnext SA (FR001400BV89:ALPHA) (the "Company"), an advanced late-clinical stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases with high unmet medical need, today announces the appointment of Scott Johnson a...
PARIS, FRANCE / ACCESSWIRE / March 31, 2021 / Pharnext SA (FR0011191287 - ALPHA) (the 'Company'), an advanced late-stage clinical biopharmaceutical company pioneering new approaches to developing innovative drug combinations based on big genomics data and artificial intelligence using its PL...
€6 million capital raise priced at market with warrants subscribed by two existing shareholders, €5 million convertible bonds issued to European investors, European investors have also provided written indication of strong interest for the potential of additional ...